Welcome to the Illinois Medical Oncology Society

Welcome to the Illinois Medical Oncology Society’s new website. We are under new management as of September 1, 2018. IMOS has contracted with HOSS (Hematology Oncology Society Services) which is a division of Next Wave Group.

 The IMOS board would also like to hear from you (all levels and types of members and potential members) about things you’d like to see for 2018- 2019 and how we can best serve your needs.

Illinois Medical Oncology Society (IMOS)

Formed on July 29, 1989, the Illinois Medical Oncology Society (IMOS) represents the common interests of a majority of the oncologists treating cancer in Illinois. As the oncology society in Illinois, we strive to provide our members with innovative resources to help them stay ahead of the shifting healthcare landscape and challenges that directly impact the high-quality care their patients deserve.

We are a State Affiliate of the American Society of Clinical Oncology.

Our Mission

We strive to promote the highest professional standards of oncology in the State of Illinois.  We create educational experiences for our members to exchange information to increase the quality of care for our patients. We act as a patient advocate to assure that patients have access to the best available care; and support and encourage clinical research against cancer.

Find out more

CMS Releases Physician Fee Schedule Final Rule
The Centers for Medicare and Medicaid Services (CMS) released the final CY 2019 Physician Fee Schedule (PFS) rule. The agency responded to the overwhelming negative stakeholder response to its proposal to revise evaluation and management (E/M) documentation requirements and payment by significantly revising its final policy.

Click here for more.

CMS Releases Final Hospital Outpatient Payment Rule - The Centers for Medicare and Medicaid Services (CMS) released the final CY 2019 Hospital Outpatient Prospective Payment System (OPPS) rule. In the Society’s comment letter, ASH requested that CMS change the status indicator for the four new Category III CPT codes for chimeric antigen receptor (CAR) T-cell therapy from “B” to “S.” In the final rule, CMS did finalize this change for one of the four codes, code 0540T, CAR-T cell administration, autologous. 

Click here for the report.


Save the Date - IMOS Spring Meeting

May 9-10, 2019
Westin, 909 N. Michigan Avenue

Highlights include:

Thursday, May 9th
Fellows Dinner at Maggiano’s, 516 N Clark St, Chicago, IL 60654
6:30 – 9:00 pm
KEYNOTE SPEAKER - Kristen Prinz, Managing Partner,

Friday, May 10th
IMOS 2019 Spring Meeting
9:00 am – 3:00 pm

  • Clinical Sessions
  • Business of Oncology
  • Legislative & Policy Pane

Registration Information coming soon!

8 Medicare and Medicaid reforms that would have the biggest impact on federal spending

Click here for more.